AbbVie drops patent rights for Kaletra antiviral treatment - (Financial Times via NewsPoints Desk)

  • According to the Medicines Patent Pool, a UN-backed non-governmental organisation, AbbVie will no longer enforce patents relating to Kaletra anywhere in the world for all formulations, reported the Financial Times.

  • The news source said the move makes AbbVie the first major drugmaker to drop its rights to generate sales from a drug that might be used during the COVID-19 pandemic.

  • The company gave notice of the change last week, according to a document seen by the Financial Times, after Israel moved to issue a compulsory licence for its use against SARS-CoV-2.

  • Kaletra, which combines the antivirals lopinavir and ritonavir, is usually used to treat HIV, but some doctors have turned to it for treating patients with coronavirus.

  • In addition, the drug's efficacy is being studied in several clinical trials, including one by the World Health Organization.

  • The company had already donated a supply to Chinese health authorities in January. However, a Chinese study of Kaletra, which was published in the NEJM last week, showed disappointing results, with no effect on outcomes.

To read more NewsPoints articles, click here.